CellaVision AB (CHIX:CEVIS) Other Long-Term Liabilities: kr87.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CEVIS CellaVision AB CHIX:CEVIS
94 GF Score
Price kr160.20
GF Value kr218.16
! 1 Warning Sign
View Full Analysis

What is CellaVision AB Other Long-Term Liabilities?

CellaVision AB CHIX:CEVIS 94 Other Long-Term Liabilities is kr87.7 Mil as of Jun. 2026. GuruFocus rates CHIX:CEVIS with a GF Score™ of 94/100 and a GF Value™ of kr218.16. The stock has 1 warning sign investors should review.

CellaVision AB's other long-term liabilities for the quarter that ended in Jun. 2026 was kr87.7 Mil.

CellaVision AB's quarterly other long-term liabilities increased from Dec. 2025 (kr84.4 Mil) to Mar. 2026 (kr86.1 Mil) and increased from Mar. 2026 (kr86.1 Mil) to Jun. 2026 (kr87.7 Mil).

CellaVision AB's annual other long-term liabilities increased from Dec. 2023 (kr64.5 Mil) to Dec. 2024 (kr75.5 Mil) and increased from Dec. 2024 (kr75.5 Mil) to Dec. 2025 (kr84.4 Mil).

CellaVision AB Other Long-Term Liabilities Related Terms

CellaVision AB Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Other Long-Term Liabilities Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.59 56.66 64.51 75.54 84.41

CellaVision AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.66 82.64 84.41 86.11 87.74
CHIX:CEVIS
94GF Score
CellaVision AB CHIX:CEVIS
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of kr87.7 Mil mean?
CellaVision AB (CHIX:CEVIS) has a Other Long-Term Liabilities of kr87.7 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CellaVision AB and its competitors.
Is CellaVision AB's Other Long-Term Liabilities too high?
CellaVision AB's current Other Long-Term Liabilities is kr87.7 Mil. Overall, CellaVision AB has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Other Long-Term Liabilities compare to ABT and SYK?
CellaVision AB's Other Long-Term Liabilities of kr87.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CellaVision AB and its competitors. CellaVision AB's current Other Long-Term Liabilities is kr87.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Other Long-Term Liabilities of kr87.7 Mil. The stock's GF Value™ is kr218.16, compared to a current price of kr160.20 — trading 26.6% below its estimated fair value. The current Other Long-Term Liabilities is kr87.7 Mil. CellaVision AB's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Other Long-Term Liabilities is kr87.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of kr160.20 is trading 26.6% below its estimated GF Value™ of kr218.16.

Key valuation signals for CHIX:CEVIS:

  • Other Long-Term Liabilities: kr87.7 Mil
  • GF Value™: kr218.16 vs. price of kr160.20 (26.6% below fair value)
  • GF Score™: 94/100 with 1 warning sign

No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
94GF Score

Get the complete analysis for CHIX:CEVIS

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr160.20
Price
kr218.16
GF Value